产品名称

LY 2886721 hydrochloride

产品货号

Axon 1964 CAS [1262036-49-6] MF C18H16F2N4O2S.HClMW 426.87 Purity: 99% Optical purity: Optically pure Soluble in DMSO Description Orally active cell-permeable inhibitor of human β-secretase (BACE-1); potential agent to treat Alzheimer's Disease References Certificates Categories Extra info M Townsend. When will Alzheimer's disease be cured? A pharmaceutical perspective. J. Alzheimers Dis. 2011, 24 (Suppl 2), 43-52. P May et al. Preclinical characterization of LY2886721: A BACE1 inhibitor in clinical development for early Alzheimer's disease. Alzheimer's & Dementia 2012, 8(4), 95. B Willis et al. Central BACE1 inhibition by LY2886721 produces opposing effects on APP processing as reflected by cerebrospinal fluid sAPPalpha and sAPPbeta. Alzheimer's & Dementia 2012, 8(4), 582. F Martenyi et al. BACE inhibitor LY2886721 safety and central and peripheral PK and PD in healthy subjects (HSs). Alzheimer's & Dementia 2012, 8(4), 583. Certificate of Analysis Material Safety Data Sheet Cell Signaling & Oncology CNS BACE-1 EC 3.4.23.46 BACE 1 inhibitor Chemical name N-(3-((4aS,7aS)-2-amino-4a,5,7,7a-tetrahydro-4H-furo[3,4-d][1,3]thiazin-7a-yl)-4-fluorophenyl)-5-fluoropicolinamide hydrochloride Parent CAS No. [1262036-50-9] Order Size Unit Price Stock 5 mg €105.00 In Stock

产品价格

现货询价，电话：010-67529703

产品规格

产品品牌

axonmedchem

产品概述

产品详情

LY 2886721 hydrochloride

Based on 8 reference(s) in Google Scholar 9 10 8

Axon 1964

CAS [1262036-49-6]

MF C18H16F2N4O2S.HCl
MW 426.87

Purity: 99%
Optical purity: Optically pure
Soluble in DMSO

LY 2886721 hydrochloride

Description

Orally active cell-permeable inhibitor of human β-secretase (BACE-1); potential agent to treat Alzheimer's Disease

M Townsend. When will Alzheimer's disease be cured? A pharmaceutical perspective. J. Alzheimers Dis. 2011, 24 (Suppl 2), 43-52.

P May et al. Preclinical characterization of LY2886721: A BACE1 inhibitor in clinical development for early Alzheimer's disease. Alzheimer's & Dementia 2012, 8(4), 95.

B Willis et al. Central BACE1 inhibition by LY2886721 produces opposing effects on APP processing as reflected by cerebrospinal fluid sAPPalpha and sAPPbeta. Alzheimer's & Dementia 2012, 8(4), 582.

F Martenyi et al. BACE inhibitor LY2886721 safety and central and peripheral PK and PD in healthy subjects (HSs). Alzheimer's & Dementia 2012, 8(4), 583.

BACE 1 inhibitor

Chemical name

N-(3-((4aS,7aS)-2-amino-4a,5,7,7a-tetrahydro-4H-furo[3,4-d][1,3]thiazin-7a-yl)-4-fluorophenyl)-5-fluoropicolinamide hydrochloride

Parent CAS No.

[1262036-50-9]

产品资料